mRNA – Medgate Today

CEPI to support development of selfamplifying mRNA vaccine technology for use against Disease X

August 9, 2023

6:01 am

CEPI to provide funding of up to US$3.6 million to advance the development of Gennova Biopharmaceutical’s self-amplifying thermostable mRNA vaccine platform to develop vaccine candidates against Disease X. • Funding will support optimisation of the technology platform to enhance immunogenicity. 8 August 2023, OSLO Norway: The Coalition for Epidemic

POST TAGS:

. Global BioPharmaceuticals CEPI COVID-19 COVID-19 pandemic Dr Melanie Saville Dr Sanjay Singh Dr Swarnendu Kaviraj Gennova immunogenicity.mRNA pandemic technology thermostability thermostable USFDA vaccinolog

Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine Manufacturers

June 2, 2023

5:16 am

News Update

admin

87% of respondents deemed mRNA a key modality for the future More than 60% vaccine makers surveyed plan revamp or new facilities for mRNA manufacturing to meet demand Skilled personnel, tech-transfer expertise, reliable supply chain, and regulatory guidelines critical to new technology adoption According

POST TAGS:

. Global APAC biohazard Governments mRNA pharmaceutical technology vaccine manufacturers

CEPI to support development of selfamplifying mRNA vaccine technology for use against Disease X

POST TAGS:

Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine Manufacturers

POST TAGS:

FIND US

ADDRESS

FOLLOW US ON SOCIAL MEDIA